Close Menu

Lung Cancer

News and reporting on lung cancer.

The firm will offer 4.7 million shares of its stock at $2.27 per share. Proceeds will go toward the development and commercialization of its tests.

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

In Q1, the US represented more than 40 percent of new Idylla instrument placements, but growth stalled due to COVID-19.

The agreement reflects Oncocyte's strategy to establish distribution partners with existing oncology channels to extend the reach of its tests globally.

The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.

A new paper outlines an upcoming effort to trace tumor development and trajectory in time and space using single-cell genetics and other genomic methods.

The approach uses activity-based nanosensor technology being commercialized by spin-out Glympse Bio to detect dysregulated protease activity linked to disease.

The approach, called Lung-CLiP, couples machine learning trained on epigenetic and clonal frequency data with the detection of alterations in blood-borne DNA.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.